From Company Creation through Public Investing
The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to publics.
Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals
Sanofi completes acquisition of Amunix
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund
